Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5332 - A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors

Date

11 Sep 2017

Session

Poster display session

Presenters

Maud Toulmonde

Citation

Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367

Authors

M. Toulmonde1, S. Cousin1, A. Bessede2, M. Homerin3, N. Stojkowitz4, M. Lusky5, M. Pulido6, A. Italiano1

Author affiliations

  • 1 Medical Oncology, Institute Bergonié, 33076 - Bordeaux/FR
  • 2 Immusmol, Immusmol, 33000 - bordeaux/FR
  • 3 Clinical Research, TRANSGENE SA, 67400 - Illkirch-Graffenstaden/FR
  • 4 Clinical Research, Transgene SA, 67400 - Illkirch-Graffenstaden/FR
  • 5 Project Management, Transgene SA, 67400 - Illkirch-Graffenstaden/FR
  • 6 Biostatistics, Institute Bergonié, 33076 - Bordeaux/FR
More

Resources

Abstract 5332

Background

JX-594 (Pexa-Vec) is a targeted oncolytic vaccinia virus designed to selectively replicate in and destroy cancer cells with epidermal growth factor receptor (EGFR)/ras pathway activation. Direct oncolysis plus GM-CSF expression is accompanied by tumor vascular disruption and anti-tumoral immunity. JX-594 was well-tolerated intravenously (IV) and intratumorally (IT). Given the immunomodulatory effects of low-dose cyclophosphamide (CP), anti-tumor synergy is predicted with JX-594.

Methods

CP was delivered orally at the dose of 50 mg BID one week on one week off. JX-594 was delivered IV at day 8 of each day 28-cycle. 2 dose levels of JX-594 were explored: 3.108 and 1.109 plaque forming units (pfu). The primary objective of the study was to determine the safety of JX-594 in combination with low-dose CP in patients with advanced solid tumors. Secondary objectives include response rates, PFS, pharmacokinetics and pharmacodynamics.

Results

Ten patients entered the study. 9 were evaluable for safety. No dose limiting toxicity was observed. The combination regimen was well-tolerated. The most frequent adverse events were grade 1-2 fever/transient flu-like symptoms (n = 10), grade 1-2 nausea (n = 5), grade 1-2 anemia (n = 4) and grade 1-2 fatigue (n = 4). 2 patients (breast cancer, ovarian cancer) had stable disease as best overall response.

Conclusions

IV JX-594 was well-tolerated in combination with low-dose CP. PK and PD (immunological profiling) will be presented at the meeting. Two phase 2 studies are ongoing in patients with advanced HER2 negative breast cancer and advanced soft-tissue sarcomas, respectively.

Clinical trial identification

NCT02630368

Legal entity responsible for the study

Institut Bergonié

Funding

INCA

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.